Omnipod
- Company typePublic
- Founded2000
- HeadquartersActon, United States
- Headcount5,001–10,000
- GTM typeB2C
- OfferingHardware or Manufacturing
Omnipod firmographics
Firmographics- Name
- Omnipod
- Legal name
- Insulet Corporation
- Website
- https://myomnipod.com
- Company type
- Public
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Ownership category
- akta.pro rank
Omnipod industry classification
Industry- Product category
- Automated Insulin Delivery / Diabetes Management Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF)
Keywords
Where Omnipod is headquartered
LocationHeadquarters
- HQ city
- Acton
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Omnipod business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Omnipod Pods (Consumables): Recurring purchase of Pods - the waterproof insulin delivery component that requires replacement every 72 hours (3 days). Sold in monthly supplies (typically 10 Pods per month). Revenue from consumables forms the recurring revenue base.
- Controllers/PDM (Devices): One-time purchase or initial kit containing the Personal Diabetes Manager (PDM) or Controller device used to operate the Pod system. Controllers are provided in introductory kits for new users.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | Omnipod 5 - Standard commercial/Medicare pricing |
| Subscription | One time/ perpetual license | Omnipod 5 Intro Kit 30-Day Trial |
| Subscription | One time/ perpetual license | Omnipod DASH 30-Day Free Trial |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Omnipod product offering
Product offeringCore offering
Omnipod (a product line of Insulet Corporation) designs, manufactures, and sells tubeless, wearable insulin delivery systems for people with insulin-dependent diabetes. Its core physical product is a disposable, body-worn "Pod" that adheres to the skin and delivers insulin via a small cannula, controlled wirelessly by a handheld Controller or smartphone app running proprietary automated insulin delivery software.
Product overview
Omnipod offers a portfolio of insulin pump therapy products for diabetes management. The core products are Omnipod 5 (automated insulin delivery system with SmartAdjust technology) and Omnipod DASH (insulin management system). Omnipod 5 integrates with CGM sensors (Dexcom G7, G6, FreeStyle Libre 2 Plus) for automated, closed-loop insulin delivery, while Omnipod DASH provides standard insulin pump therapy without automation. The portfolio includes the tubeless, waterproof Pod device (72-hour wear), Controller/PDM devices, and the Omnipod 5 smartphone App. SmartAdjust technology and SmartBolus Calculator are key algorithmic capabilities that differentiate Omnipod 5.
Differentiator
Problem solved
Functional benefit
Brands
- PodderCentral: Support resources and login portal for Omnipod users
- Podder Talk
- SmartAdjust
Products and services
- Omnipod 5 Automated Insulin Delivery System Tubeless, wearable insulin delivery system that automatically adjusts insulin delivery every five minutes using the proprietary SmartAdjust algorithm based on real-time readings from a compatible continuous glucose monitor (Dexcom G6/G7 or FreeStyle Libre 2 Plus), controlled wirelessly via smartphone app or handheld Controller. Intended for people with insulin-dependent type 1 and type 2 diabetes.
- Omnipod DASH Insulin Management System Tubeless, wearable insulin pump with a touchscreen handheld Controller delivering personalized insulin dosing via the SmartBolus Calculator; designed for people with insulin-dependent diabetes who do not require or want full closed-loop automation.
- Omnipod Pod (Insulin Reservoir) Disposable, waterproof, body-worn insulin reservoir that adheres to the skin and delivers continuous subcutaneous insulin for up to 72 hours before replacement; sold as the recurring consumable for the Omnipod platform.
- Omnipod 5 Controller Dedicated handheld touchscreen controller provided with the Omnipod 5 system for users who prefer a non-smartphone interface, communicating wirelessly with the Pod and connected CGM.
- Omnipod 5 App Free, downloadable smartphone application that allows users of the Omnipod 5 system to control the Pod and view CGM data directly from a compatible iOS or Android phone, in lieu of the handheld Controller.
Quantifiable outcome
- Average time in target glucose range improved from 52.5% to 68% in children (ages 2-5.9 years) after 3 months of Omnipod 5 Automated Mode use.
- +7 more outcomes
Companies that use Omnipod
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles2 records
Omnipod technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
AI capability4 records
Feature5 records
Omnipod partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and flagship.
- DexcomcoreDexcom is a key CGM technology partner for Omnipod. The Omnipod 5 system is compatible with Dexcom G7 and G6 CGM sensors for automated insulin delivery. This integration enables the SmartAdjust technology to automatically adjust insulin delivery based on real-time glucose data. The partnership is highlighted in Dexcom's educational materials about insulin pump compatibility.
- Abbott (FreeStyle Libre)coreAbbott's FreeStyle Libre sensors are integrated with Omnipod insulin pumps as part of automated insulin delivery systems. The partnership focuses on health partnerships for diabetes management, combining CGM technology with insulin delivery for improved glucose regulation.
- MarvelflagshipOmnipod collaborated with Marvel to create 'Dyasonic' - a superhero character featured in a custom Marvel comic. This creative collaboration celebrates representation for the diabetes community and serves as a major marketing initiative. The comic features Omnipod 5 on her arm, demonstrating the product's integration with glucose monitoring and the benefits of time in range.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Omnipod competitors and assessment
Company assessmentBroad incumbents
- Abbott Diabetes Care: Abbott's FreeStyle Libre CGM family (including Libre 2 Plus) integrates with Omnipod 5 and is the second major CGM platform Omnipod supports. Abbott is an adjacent incumbent in diabetes management, having acquired Bigfoot Biomedical, signaling possible future entry into pump delivery.
- Roche Diabetes Care: Roche's Diabetes Care business (Accu-Chek) offers insulin pumps and integrated diabetes management tools within its much larger diagnostics and pharma portfolio. It overlaps with Omnipod in pump and BGM/CGM-based diabetes management but is not a tubeless-AID specialist.
Emerging players
- CeQur: CeQur develops wearable, disposable insulin delivery patches (PaQ) targeting simplification of mealtime insulin for T2D patients. It addresses an overlapping patient need (T2D insulin delivery) with a different, simpler patch form factor than Omnipod 5.
- SOOIL Developments: SOOIL manufactures the Dana-i and Dana RS insulin pumps, which integrate with various CGMs and Loop-compatible AID systems. It is a smaller, internationally distributed competitor with comparable patch-form-factor ambitions to Omnipod.
- Beta Bionics: Beta Bionics markets the iLet bionic pancreas, an automated insulin delivery system using a proprietary algorithm and integrated CGM. It competes with Omnipod 5 in the T1D AID category but is earlier in commercial scale and primarily focused on the US market.
- ViCentra: ViCentra's Kaleido insulin pump is a small, wearable patch pump available in select European markets with Loop AID compatibility. It competes with Omnipod on form factor and discretion rather than on installed base scale or geographic breadth.
Direct peers
- Tandem Diabetes Care: Tandem's t:slim X2 insulin pump with Control-IQ algorithm is a leading AID system integrated with Dexcom CGMs, competing head-to-head with Omnipod 5. Both companies target endocrinologists and pump candidates with prescription-based, recurring consumables revenue models.
- Medtronic: Medtronic's Diabetes division offers the MiniMed 780G automated insulin delivery system with SmartGuard technology, directly competing with Omnipod 5 in tubed AID and increasingly in tubeless form factors. Both target the same T1D and insulin-requiring T2D patient populations via prescription channels.
Regional players
- Ypsomed: Ypsomed offers the mylife YpsoPump and the mylife Loop AID system, primarily across European markets. Comparable to Omnipod as a patch/tubeless-style insulin pump with CGM-driven automation, but with much stronger European distribution and limited US presence.
Others
- Dexcom: Dexcom is a key technology partner whose G6 and G7 CGMs power Omnipod 5's SmartAdjust algorithm. As a CGM incumbent, it is an ecosystem participant rather than a direct pump competitor, but its roadmap, pricing, and partnership terms materially shape Omnipod's clinical and commercial position.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Omnipod social profiles
Digital presenceOmnipod financial estimates
Financial estimateRevenue estimate
Valuation estimate
Omnipod leadership team
Management profileNumber of profiles
Omnipod funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Omnipod M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Omnipod
What does Omnipod do?
Omnipod (a product line of Insulet Corporation) designs, manufactures, and sells tubeless, wearable insulin delivery systems for people with insulin-dependent diabetes. Its core physical product is a disposable, body-worn "Pod" that adheres to the skin and delivers insulin via a small cannula, controlled wirelessly by a handheld Controller or smartphone app running proprietary automated insulin delivery software.
Is Omnipod a public or private company?
Omnipod is a public company. It is classified as public and is currently operating.
When was Omnipod founded?
Omnipod was founded in 2000. It employs 5,001 to 10,000 people.
Where is Omnipod based?
Omnipod is headquartered in Acton, United States, in the North America region.
How does Omnipod make money?
Two revenue lines are on record. Omnipod Pods (Consumables) is the primary driver. The others are controllers/PDM (Devices).
Who are Omnipod's main competitors?
Broad incumbents on record are Abbott Diabetes Care and Roche Diabetes Care. Emerging players are CeQur, SOOIL Developments, Beta Bionics and ViCentra. Direct peers are Tandem Diabetes Care and Medtronic. Ypsomed is listed as a regional player. Dexcom is listed as an others.
Does Omnipod have an API?
No public API is recorded for Omnipod.
What industry is Omnipod in?
Omnipod's product category is Automated Insulin Delivery / Diabetes Management Devices. Its primary akta.pro industry code is HLAHAHAF, Automated Insulin Delivery (AID) / Closed-Loop Systems. Its NAICS code is 334510 and its SIC code is 3845.